Stray Dog

Senator asks FDA and FTC to investigate HIMS

  • Bad news: Senator Jim Banks asked the FDA and FTC to jointly investigate HIMS over its ad claims, Zepbound pricing and subscription refunds.
  • Mixed: It is a letter applying pressure, not a formal investigation or enforcement action, so near-term impact is limited.
  • Neutral: Shares closed at $26.19 (down 6.5%), mainly on the broad market rather than anything specific to HIMS.
Read the full notes

Senator Jim Banks (Republican, Indiana) has written to the FDA calling for a multi-agency investigation into three compliance issues at HIMS. The chain of regulatory pressure keeps getting longer, but there is no real enforcement risk in the near term.

Key insights

  • On 3 Jun Senator Jim Banks wrote to acting FDA Commissioner Kyle Diamantas, asking the FDA and FTC to investigate HIMS jointly.
  • The requested inquiry covers three issues: whether the Super Bowl ad overstated efficacy, Zepbound KwikPen pricing more than 500% above the TrumpRx most-favoured-nation price, and multi-month subscriptions that do not refund unused medication.
  • Banks's core argument is that HIMS's pricing and marketing are undermining TrumpRx's goal of lowering drug prices.
  • The regulatory narrative keeps escalating: FDA enforcement in February, then a DOJ referral, now public pressure from a senator.
  • The real short-term impact is limited. This is a member of Congress applying pressure by letter, not a formal investigation or enforcement action.
  • Watch whether the FDA responds formally and whether this turns into an FTC consumer-protection investigation.

Price action

Closed Friday at $26.19 (-6.5%), dragged down mainly by the broad market rather than anything specific to HIMS: payrolls beat expectations, rate-hike expectations rose and the Nasdaq fell 4%.

Risk flag

Political-label risk: HIMS is being cast as standing against TrumpRx, a damaging position in the current political climate.

Catalysts to watch

  • 11 Jun annual shareholder meeting: votes on CEO pay and Kofi Amoo-Gottfried's board nomination

Sources 1

  1. Washington Reporter (obtained the full text of Banks's letter exclusively)